NCT05022927View on ClinicalTrials.gov

A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

ERY974

ERY974 vial

DRUG

Tocilicumab

Tocilizumab vial

DRUG

Atezolizumab

Atezolizumab vial

DRUG

Bevacizumab

Bevacizumab vial

Trial Locations (11)

100

National Taiwan University Hospital, Taipei

33305

Linkou Chang Gung Memorial Hospital, Taoyuan District

40705

Taichung Veterans General Hospital, Taichung

70142

National Cheng Kung University Hospital, Tainan City

71004

Chi Mei Medical Center, Tainan City

83301

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

260-8677

Chiba University Hospital, Chiba

277-8577

National Cancer Center Hospital East, Kashiwa

241-8515

Kanagawa Cancer Center, Yokohama

589-8511

Kindai University Hospital, Sayama

104-0045

National Cancer Center Hospital, Chuo Ku

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY